Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rangering i aksjer #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Aksjekurs
$0.00244926
Markedsverdi
$51.67K
Endring (1 dag)
5.88%
Endring (1 år)
110.15%
Land
GB
Handel Nuformix plc (NFX)

Kategori

EPS for Nuformix plc (NFX)
EPS per September 2025 TTM: $0.00
Ifølge de siste økonomiske rapportene og aksjekursen til Nuformix plc er selskapets nåværende EPS (TTM) $0.00. Ved slutten av 2024 hadde selskapet en EPS på $-0.01, en nedgang sammenlignet med EPS-en i 2023 som var $0.00.
EPS-historikk for Nuformix plc fra 2014 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) 0.00 -100.00%
2025 0.00 -100.00%
2024 $-0.01 520.00%
2023 0.00 -60.00%
2022 0.00 -16.67%
2021 0.00 50.00%
2020 0.00 -57.45%
2019 0.00 -31.88%
2018 $-0.01 -23.33%
2017 $-0.01 8.43%
2016 $-0.01 0.00%
2014 0.00 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$3.62 -402,577.78%
DK
$15.47 -1,718,988.89%
US
$43.12 -4,791,211.11%
US
$9.62 -1,069,077.78%
BE
$2.98 -331,211.11%
AU